Gilead Sciences Dividends and Buybacks
Dividend criteria checks 5/6
Gilead Sciences is a dividend paying company with a current yield of 2.93% that is well covered by earnings. Next payment date is on 27th June, 2025 with an ex-dividend date of 13th June, 2025.
Key information
2.9%
Dividend yield
0.7%
Buyback Yield
| Total Shareholder Yield | 3.6% |
| Future Dividend Yield | 3.3% |
| Dividend Growth | 8.1% |
| Next dividend pay date | 27 Jun 25 |
| Ex dividend date | 13 Jun 25 |
| Dividend per share | n/a |
| Payout ratio | 65% |
Recent dividend and buyback updates
Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79
Mar 12
Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's
Feb 18Recent updates
Statutory Profit Doesn't Reflect How Good Gilead Sciences' (NASDAQ:GILD) Earnings Are
May 15Gilead Sciences Q1 Earnings Review: HIV Division Masks Underperformance
Apr 25Revenues Working Against Gilead Sciences, Inc.'s (NASDAQ:GILD) Share Price
Apr 15
New HIV, Livdelzi And CAR T Options Will Expand Reach
Gilead's innovation in HIV and oncology treatments supports revenue growth and market expansion in these therapeutic areas.Gilead: Growth Constraints Lead To Rating Downgrade Following 50% Rally
Mar 16Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79
Mar 12Why Gilead Sciences Remains A Buy After A 40% Rally
Feb 27Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's
Feb 18Gilead Sciences: Diversification Strategy Not Derisked Enough Yet
Feb 11Gilead Sciences (NASDAQ:GILD) Could Easily Take On More Debt
Feb 09Gilead: Strong Sales Growth Remains With Veklury And Beyond
Feb 03Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise
Dec 29Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure
Dec 18Gilead Sciences, Inc.'s (NASDAQ:GILD) Business And Shares Still Trailing The Industry
Dec 13We Think You Can Look Beyond Gilead Sciences' (NASDAQ:GILD) Lackluster Earnings
Nov 13Why Gilead's Solid Q3 Earnings Could Point To A Dividend Surprise Next Year
Nov 07Gilead Sciences: My Worst Stock Move In 2024, And What I Learned From It
Oct 01Gilead Sciences: Buy This Bargain Before It's Gone
Aug 30Gilead's New Anti-Obesity Drug: The Real Reason Behind The 25% Stock Surge?
Aug 05A Look At Gilead Sciences After Its Recent Weakness
Jul 27Gilead Records Positive Phase III Results In HIV
Jun 22Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?
Jun 13Upcoming Dividend Payment
Stability and Growth of Payments
Fetching dividends data
Stable Dividend: GILD's dividends per share have been stable in the past 10 years.
Growing Dividend: GILD's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
| Gilead Sciences Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (GILD) | 2.9% |
| Market Bottom 25% (US) | 1.6% |
| Market Top 25% (US) | 4.8% |
| Industry Average (Biotechs) | 2.2% |
| Analyst forecast (GILD) (up to 3 years) | 3.3% |
Notable Dividend: GILD's dividend (2.93%) is higher than the bottom 25% of dividend payers in the US market (1.57%).
High Dividend: GILD's dividend (2.93%) is low compared to the top 25% of dividend payers in the US market (4.79%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (64.8%), GILD's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (39.9%), GILD's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/21 09:43 |
| End of Day Share Price | 2025/05/21 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gilead Sciences, Inc. is covered by 71 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| Ishan Majumdar | Baptista Research |